Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis

  • 72 Accesses


Since psoriasis is an immuno-mediated skin disease, long-term therapies are necessary for its treatment. In clinical investigations, tacrolimus (TAC), a macrolide immunosuppressive inhibitor of calcineurin, arises as an alternative for the treatment of psoriasis, acting in some cytokines involved in the pathogenesis of the disease. Here, we aim to study the psoriasis treatment with TAC and siRNA for one of most cytokines expressed in psoriasis, the TNF-α. A multifunctional nanostructure lipid carrier (NLC) was developed to co-delivery TAC and siRNA. Results showed that the particle size and zeta potential were around 230 nm and + 10 mV, respectively. The release study demonstrated a controlled release of TAC, and the permeation and retention profile in the skin tissue show to be promising for topical application. The cell viability and uptake in murine fibroblast presented low toxicity associated to uptake of NLC in 4 h, and finally, the in vivo animal model demonstrates the efficiency of the NLC multifunctional, exhibiting a reduction of the cytokine TNF-α expression about 7-fold and presenting a synergic effect between the TAC and TNF-α siRNA. The developed system was successfully to treat in vivo psoriatic animal model induced by imiquimod and the synergic combination was reported here for the first time.

Graphical abstract

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8


  1. 1.

    Xu X, Zhang HY. The immunogenetics of psoriasis and implications for drug repositioning. Int J Mol Sci. 2017;18:2650.

  2. 2.

    Woo YR, Cho DH, Park HJ. Molecular mechanisms and management of a cutaneous inflammatory disorder: psoriasis. Int J Mol Sci. 2017;18:2684.

  3. 3.

    Malakou LS, Gargalionis AN, Piperi C, et al. Molecular mechanisms of mechanotransduction in psoriasis. Ann Transl Med. 2018;6:245.

  4. 4.

    Sala M, Elaissari A, Fessi H. Advances in psoriasis physiopathology and treatments: up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). J Control Release. 2016;239:182–202.

  5. 5.

    Albanesi C, Madonna S, Gisondi P, et al. The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front Immunol. 2018;9:1–7.

  6. 6.

    Chiricozzi A, Romanelli P, Volpe E, et al. Scanning the immunopathogenesis of psoriasis. Int J Mol Sci. 2018;19:179.

  7. 7.

    Mitra A, Wu Y. Topical delivery for the treatment of psoriasis. Expert Opin Drug Deliv. 2010;7:977–92.

  8. 8.

    Khalil S, Bardawil T, Stephan C, et al. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatolog Treat. 2017;28:684–96.

  9. 9.

    Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18:2297.

  10. 10.

    Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54:102–13.

  11. 11.

    Chiricozzi A, Pitocco R, Saraceno R, et al. New topical treatments for psoriasis. Expert Opin Pharmacother. 2014;15:461–70.

  12. 12.

    Bracke S, Desmet E, Guerrero-Aspizua S, Tjabringa SG, Schalkwijk J, van Gele M, et al. Identifying targets for topical RNAi therapeutics in psoriasis: assessment of a new in vitro psoriasis model. Arch Dermatol Res. 2013;305:501–12.

  13. 13.

    Desmet E, Van Gele M, Grine L, et al. Towards the development of a RNAi-based topical treatment for psoriasis: proof-of-concept in a 3D psoriasis skin model. Exp Dermatol. 2018;27:463–9.

  14. 14.

    Pradhan M, Alexander A, Singh MR, Singh D, Saraf S, Saraf S, et al. Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed Pharmacother. 2018;107:447–63.

  15. 15.

    Malecic N, Young H. Tacrolimus for the management of psoriasis: clinical utility and place in therapy. Psoriasis (Auck). 2016;6:153–63.

  16. 16.

    Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg. 2014;18:8–14.

  17. 17.

    Kravvas G, Gholam K. Use of topical therapies for pediatric psoriasis: a systematic review. Pediatr Dermatol. 2018;35:296–302.

  18. 18.

    Dheer D, Jyoti, Gupta PN, et al. Tacrolimus: an updated review on delivering strategies for multifarious diseases. Eur J Pharm Sci. 2018;114:217–27.

  19. 19.

    Shoughy SS. Topical tacrolimus in anterior segment inflammatory disorders. Eye Vis. 2017;4:7.

  20. 20.

    Tatiparti K, Sau S, Kashaw S, et al. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials. 2017;7:77.

  21. 21.

    Dana H, Chalbatani GM, Mahmoodzadeh H, et al. Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci. 2017;13:48–57.

  22. 22.

    Kaczmarek JC, Kowalski PS, Anderson DG. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017;9:1–16.

  23. 23.

    Rosa J, Suzuki I, Kravicz M, et al. Current non-viral siRNA delivery systems as a promising treatment of skin diseases. Curr Pharm Des. 2018;24:2644–63.

  24. 24.

    Desai PR, Marepally S, Patel AR, et al. Topical delivery of anti-TNF α siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release. 2013;170:51–63.

  25. 25.

    Petrilli R, Eloy JO, Praça FSG, del Ciampo J, Fantini MA, Fonseca MJ, et al. Liquid crystalline nanodispersions functionalized with cell-penetrating peptides for topical delivery of short-interfering RNAs: a proposal for silencing a pro-inflammatory cytokine in cutaneous diseases. J Biomed Nanotechnol. 2016;12:1063–75.

  26. 26.

    Raphael AP, Garrastazu G, Sonvico F, Prow TW. Formulation design for topical drug and nanoparticle treatment of skin disease. Ther Deliv. 2015;6:197–216.

  27. 27.

    Vogt A, Wischke C, Neffe AT, et al. Nanocarriers for drug delivery into and through the skin—do existing technologies match clinical challenges? J Control Release. 2016;242:3–15.

  28. 28.

    Kaur A, Katiyar SS, Kushwah V, et al. Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomedicine. 2017;13:1473–82.

  29. 29.

    Agrawal U, Gupta M, Jadon RS. Multifunctional nanomedicines: potentials and prospects. Drug Deliv. and Transl. Res. 2012;3:479–97.

  30. 30.

    Roberts MS, Mohammed Y, Pastore MN, et al. Topical and cutaneous delivery using nanosystems. J Control Release. 2017;247:86–105.

  31. 31.

    Garcês A, Amaral MH, Sousa Lobo JM, Silva AC. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: a review. Eur J Pharm Sci. 2018;112:159–67.

  32. 32.

    Sala M, Diab R, Elaissari A, Fessi H. Lipid nanocarriers as skin drug delivery systems: properties, mechanisms of skin interactions and medical applications. Int J Pharm. 2018;535:1.

  33. 33.

    The European Agency for the Evaluation of Medicinal Products. Note for guidance on validation of analytical procedures: Methodology. 1996;9.

  34. 34.

    Cavalcanti SMT, Nunes C, Costa Lima SA, Soares-Sobrinho JL, Reis S. Optimization of nanostructured lipid carriers for Zidovudine delivery using a microwave-assisted production method. Eur J Pharm Sci. 2018;122:22–30.

  35. 35.

    Aldayel AM, O’Mary HL, Valdes SA, et al. Lipid nanoparticles with minimum burst release of TNF-α siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate. J Control Release. 2018;283:280–9.

  36. 36.

    Vivas-Mejia PE, JMR G. Nanoliposomal c-myc siRNA inhibits tumor growth of sisplatin-resistant ovarian cancer. USA Patent number: US9895312. 2018:25.

  37. 37.

    Ich Harmonised Tripartite Guideline. Evaluation for stability data Q1E. Harmon Tripart Guidel. 2003;19.

  38. 38.

    Tofani LB, Depieri LV, Campos PM, et al. In vitro tyRP-1 knock-down based on siRNA carried by liquid crystalline nanodispersions: an alternative approach for topical treatment of vitiligo. 2018;35:104.

  39. 39.

    Praça FSG, Medina WSG, Eloy JO, Petrilli R, Campos PM, Ascenso A, et al. Evaluation of critical parameters for in vitro skin permeation and penetration studies using animal skin models. Eur J Pharm Sci. 2018;111:121–32.

  40. 40.

    OECD. Guideline for thetesting of chemicals: skin absorption in vitro method. Guidel Test Chem. 2004.

  41. 41.

    Fits L Van Der, Mourits S, Voerman JSA, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. 2009;182:5836–45.

  42. 42.

    Cun D, Tong HHY. Comparison of normal versus imiquimod-induced psoriatic skin in mice for penetration of drugs and nano-particles. 2018;13:5625–35.

  43. 43.

    Boakye CHA, Patel K, Doddapaneni R, et al. Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment. J Control Release. 2017;246:120–32.

  44. 44.

    Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3:e00149.

  45. 45.

    Lin CW, Jan MS, Kuo JHS. The vector-related influences of autophagic microRNA delivery by lipofectamine 2000 and polyethylenimine 25K on mouse embryonic fibroblast cells. Eur J Pharm Sci. 2017;101:11–21.

  46. 46.

    Cardarelli F, Digiacomo L, Marchini C, et al. The intracellular trafficking mechanism of lipofectamine-based transfection reagents and its implication for gene delivery. Sci Rep. 2016;6:1–8.

  47. 47.

    Danaei M, Dehghankhold M, Ataei S, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10:1–17.

  48. 48.

    Wan T, Pan W, Long Y, Yu K, Liu S, Ruan W, et al. Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities. Int J Nanomedicine. 2017;12:1485–97.

  49. 49.

    Zhuo F, Abourehab MAS, Hussain Z. Hyaluronic acid decorated tacrolimus-loaded nanoparticles: efficient approach to maximize dermal targeting and anti-dermatitis efficacy. Carbohydr Polym. 2018;197:478–89.

  50. 50.

    Dantas IL, Bastos KTS, Machado M, et al. Influence of stearic acid and beeswax as solid lipid matrix of lipid nanoparticles containing tacrolimus. J Therm Anal Calorim. 2018;132:1557–66.

  51. 51.

    Molinaro R, Wolfram J, Federico C, Cilurzo F, di Marzio L, Ventura CA, et al. Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors. Expert Opin Drug Deliv. 2013;10:1653–68.

  52. 52.

    Neuberg P, Kichler A. Recent developments in nucleic acid delivery with polyethylenimines. Adv. Genet. Elsevier; 2014;88:263–88.

  53. 53.

    Pandey AP, Sawant KK. Polyethylenimine: a versatile, multifunctional non-viral vector for nucleic acid delivery. Mater Sci Eng C Mater Biol Appl. 2016;68:904–18.

  54. 54.

    Depieri LV, Borgheti-Cardoso LN, Campos PM, et al. RNAi mediated IL-6 in vitro knockdown in psoriasis skin model with topical siRNA delivery system based on liquid crystalline phase. Eur J Pharm Biopharm. 2016;105:50–8.

  55. 55.

    Borgheti-Cardoso LN, Depieri LV, Kooijmans SAA, Diniz H, Calzzani RA, Vicentini FT, et al. An in situ gelling liquid crystalline system based on monoglycerides and polyethylenimine for local delivery of siRNAs. Eur J Pharm Sci. 2015;74:103–17.

  56. 56.

    Vicentini FTMDC, Depieri LV, Polizello ACM, del Ciampo J, Spadaro AC, Fantini MC, et al. Liquid crystalline phase nanodispersions enable skin delivery of siRNA. Eur J Pharm Biopharm. 2013;83:16–24.

  57. 57.

    Ewe A, Höbel S, Heine C, et al. Optimized polyethylenimine (PEI 912)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model. Drug Deliv Transl Res. 2016;7:206–16.

  58. 58.

    Kravicz MH, Balogh DT, Kar M, et al. Influence of alkyl chains of modified polysuccinimide-based polycationic polymers on polyplex formation and transfection. Macromol Biosci. 2019;19:1–14.

  59. 59.

    Sato Y, Matsui H, Sato R, Harashima H. Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA. J Control Release. 2018;284:179–87.

  60. 60.

    Borgheti-Cardoso LN, Kooijmans SAA, Fens MHAM, van der Meel R, Vicentini FTMC, Fantini MCA, et al. In situ gelling liquid crystalline system as local siRNA delivery system. Mol Pharm. 2017;14:1681–90.

  61. 61.

    Scholz C, Wagner E. Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. J Control Release. 2012;161:554–65.

  62. 62.

    Savić V, Todosijević M, Ilić T, Lukić M, Mitsou E, Papadimitriou V, et al. Tacrolimus loaded biocompatible lecithin-based microemulsions with improved skin penetration: structure characterization and in vitro/in vivo performances. Int J Pharm. 2017;529:491–505.

  63. 63.

    Shastri DH. Effective delivery routes and strategies for solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). Curr Pharm Des. 2018;23:6592–601.

  64. 64.

    Gupta S, Kesarla R, Chotai N, et al. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. Biomed Res Int. 2017;2017:5984014.

  65. 65.

    Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure preparation and application. Adv Pharm Bull. 2015;5:305–13.

  66. 66.

    Banerjee R. Overcoming the stratum corneum barrier : a nano approach. Drug Deliv Transl Res. 2013;3:205–8.

  67. 67.

    Nam SH, Ji XY, Park JS. Investigation of tacrolimus loaded nanostructured lipid carriers for topical drug delivery. Bull Kor Chem Soc. 2011;32:956–60.

  68. 68.

    Thapa RK, Yoo BK. Evaluation of the effect of tacrolimus-loaded liquid crystalline nanoparticles on psoriasis-like skin inflammation. J Dermatolog Treat. 2014;25:22–5.

  69. 69.

    Gabriel D, Mugnier T, Courthion H, et al. Improved topical delivery of tacrolimus: a novel composite hydrogel formulation for the treatment of psoriasis. J Control Release. 2016;242:16–24.

  70. 70.

    Jain A, Doppalapudi S, Domb AJ, et al. Tacrolimus and curcumin co-loaded liposphere gel: synergistic combination towards management of psoriasis. J Control Release. 2016;243:132–45.

  71. 71.

    Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;103:598–613.

  72. 72.

    Hall A, Lächelt U, Bartek J, et al. Polyplex evolution: understanding biology, Optimizing Performance. Mol Ther. 2017;25:1476–90.

  73. 73.

    Abd El-Hamid BN, Swarnakar NK, Soliman GM, et al. High payload nanostructured lipid carriers fabricated with alendronate/polyethyleneimine ion complexes. Int J Pharm. 2018;535:148–56.

  74. 74.

    Kafil V, Omidi Y. Cytotoxic impacts of linear and branched polyethylenimine nanostructures in A431 cells. BioImpacts. 2011;1:23–30.

  75. 75.

    Castan L, José da Silva C, Ferreira Molina E, et al. Comparative study of cytotoxicity and genotoxicity of commercial Jeffamines® and polyethylenimine in CHO-K1 cells. J Biomed Mater Res B Appl Biomater. 2018;106:742–50.

  76. 76.

    Pischon H, Radbruch M, Ostrowski A, et al. Stratum corneum targeting by dendritic core-multishell-nanocarriers in a mouse model of psoriasis. Nanomedicine. 2017;13:317–27.

  77. 77.

    Jain A, Pooladanda V, Bulbake U, et al. Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis. Nanomedicine. 2017;13:2251–62.

  78. 78.

    Pischon H, Radbruch M, Ostrowski A, et al. How effective is tacrolimus in the imiquimod-induced mouse model of psoriasis? J Invest Dermatol. 2017;138:455–58.

  79. 79.

    Kang NW, Kim MH, Sohn SY, Kim KT, Park JH, Lee SY, et al. Curcumin-loaded lipid-hybridized cellulose nanofiber film ameliorates imiquimod-induced psoriasis-like dermatitis in mice. Biomaterials. 2018;182:245–58.

  80. 80.

    Sharma G, Devi N, Thakur K, et al. Lanolin-based organogel of salicylic acid: evidences of better dermatokinetic profile in imiquimod-induced keratolytic therapy in BALB/c mice model. 2017;8:398–413.

  81. 81.

    Marepally S, Boakye CH, Patel AR, Godugu C, Doddapaneni R, Desai PR, et al. Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine. 2014;9:2157–74.

  82. 82.

    Wan T, Pan J, Long Y, et al. Dual roles of TPGS based microemulsion for tacrolimus: enhancing the percutaneous delivery and anti-psoriatic efficacy. Int J Pharm. 2017;528:511–23.

Download references


This work was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and the National Institute of Science and Technology in Pharmaceutical Nanotechnology, a transdisciplinary approach INCT-NANOFARMA, which is supported by São Paulo Research Foundation (FAPESP, Brazil) grant #2014/50928-2 and by “Conselho Nacional de Desenvolvimento Científico e Tecnológico” (CNPq, Brazil) grant #465687/2014-8.

Author information

Correspondence to Maria Vitória Lopes Badra Bentley.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Consent for animal studies

The protocol of in vivo animal studies (the “In vivo studies” section) is in accordance with the National Animal Experiment Control Board and is registered under the number 18.1.385.60.2 by the School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Brazil.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Viegas, J.S.R., Praça, F.G., Caron, A.L. et al. Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis. Drug Deliv. and Transl. Res. (2020). https://doi.org/10.1007/s13346-020-00723-6

Download citation


  • Tacrolimus
  • Nanoparticle
  • Psoriasis
  • Topical application
  • Gene therapy